NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

Rhodionin and rhodionin can inhibit cytochrome P450 2D6 non-competitively with high specificity which could have implications for interactions with co-administered drugs; they can significantly suppress the elevation of the postprandial blood triglyceride level suggests that they may be to the treatment of lifestyle-related diseases such as hyperlipidemia and exogeneous obesity and to health foods.

Anemosapogenin shows potent anti-tumor effect in vivo, but it has some toxicity, structure modification should be needed.